

IMI – Revolutionising Europe's Pharmaceutical Industry

IMI Matters!

**Session in the Framework of the Event
Joint Technology Initiatives – Innovation in Action
4-6 October 2011 – European Parliament – Brussels**



**EUROPEAN
COMMISSION**

**EU - BUILDING AN
INNOVATION UNION**

Programme of Session IMI Matters!

- **Welcome – Mario Mauro, MEP**
- **Introducing IMI – Rudolf Strohmeier, Deputy Director-General Scientific Advances, Directorate-General for Research and Innovation, European Commission**
- **Why IMI matters to the EU's health research goals – Maria Vidal, Head of the Medical Research Unit, Directorate-General for Research and Innovation, European Commission**
- **Why IMI matters to Europe's pharmaceutical industry – Richard Bergström, Director General, EFPIA**
- **Why IMI matters to patients – Mary Baker, MBE, President, European Brain Council; President, European Federation of Neurological Associations**



IMI – Revolutionising Europe's Pharmaceutical Industry

IMI Matters!

Introducing IMI

Rudolf W. Strohmeier
Deputy Director-General
DG Research & Innovation



EUROPEAN
COMMISSION


EU - BUILDING AN
INNOVATION UNION

Rationale for Launching the Innovative Medicines Initiative

- Decline in R&D industrial productivity despite steadily increasing R&D expenditures
- => research bottlenecks in the drug development process
- Loss of European competitiveness in the sector
- Europe is good at putting stakeholders together, based on the EU experience from the Framework Programmes
- Europe has the potential and capacity of innovation, based on a tissue of entrepreneurial universities and SMEs
- Common initiative EC – Pharma industry
- Faster and better drugs for the patient



Objectives of IMI



Better and faster medicines for patients



EUROPEAN
COMMISSION

EU - BUILDING AN
INNOVATION UNION

Horizon 2020 – Key features

Clear set of objectives based on Europe 2020 and Innovation Union

Integrating research and innovation in a **seamless programme**

Focus on overall policy priorities – **grand challenges**

Programme **structured by objectives**

Simpler funding landscape for research and innovation with common rules and funding schemes



Horizon 2020 – Objectives and structure

Europe 2020 priorities

International cooperation

European Research Area

Shared objectives and principles

Tackling Societal Challenges

- Health, demographic change and wellbeing
- Food security and the bio-based economy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Supply of raw materials, resource efficiency and climate action
- Inclusive, innovative and secure societies

EIT will contribute to addressing these challenges

Creating Industrial Leadership and Competitive Frameworks

- Leadership in enabling and industrial technologies
- Access to risk finance
- Innovation in SMEs

Excellence in the Science Base

- Frontier research (ERC)
- Future and Emerging Technologies (FET)
- Skills and career development (Marie Curie)
- Research infrastructures

Common rules, toolkit of funding schemes

Simplified access

Coherent with other EU and MS actions



EUROPEAN
COMMISSION

EU - BUILDING AN
INNOVATION UNION

Next Steps for Horizon 2020

Thematic **informal consultation workshops** took place in **July**

Commission proposals for **Horizon 2020**: before the end of 2011

Legislative decisions on Horizon 2020 by the Council and European Parliament (2012-13): during 2013

Horizon 2020 (from 2014)

Find out more at

http://ec.europa.eu/research/horizon2020/index_en.cfm?pg=home



EUROPEAN
COMMISSION

EU - BUILDING AN
INNOVATION UNION

Perspective for IMI under Horizon 2020

Criteria for continuation or launch of PPPs

- Added value of acting at EU level;
- Scale of impact on industrial competitiveness, sustainable growth and/or socio-economic issues;
- Long-term commitment from all partners based on a shared vision and clearly defined objectives;
- Scale of the resources involved, and ability to leverage additional investments in research and innovation;
- Clearly defined roles for each of the partners and agreed key performance indicators over the period chosen.



Modifications to Further Improve Functioning of IMI

- More flexible launching of calls, several times per year
- Accepting a set percentage of in-kind contribution of EFPIA companies from outside of Europe

